What is Treventis?
Treventis Corporation is at the forefront of tackling debilitating protein misfolding diseases, leveraging its proprietary Common Conformational Morphology (CCM) technology. The company employs a patented discovery engine designed to pinpoint druggable active sites within misfolded protein targets. Its lead program, a collaboration with Takeda, focuses on creating anti-misfolding small molecules for Alzheimer's disease. Beyond this, Treventis is also engaged in research funded by the U.S. Department of Defense, exploring applications in oncology and other neurodegenerative conditions, demonstrating the broad applicability of its innovative platform.
How much funding has Treventis raised?
Treventis has raised a total of $4.4M across 1 funding round:
Unspecified
$4.4M
Unspecified (2013): $4.4M, investors not publicly disclosed
What's next for Treventis?
The substantial enterprise-level funding and recent strategic investment signal a pivotal growth phase for Treventis. This capital is expected to accelerate the advancement of its Alzheimer's program and further explore its therapeutic potential in oncology and other neurodegenerative diseases. The company's focus on a versatile technology platform positions it for significant expansion and potential partnerships within the pharmaceutical and biotechnology sectors.
See full Treventis company page
